

A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the clinical efficacy of a single intrapyloric injection of botulinum toxin type A (Botox®) in patients with idiopathic gastroparesis. The BIG study.

Submission date 09/06/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 09/06/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 09/06/2006	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr J.J.L. Haans

Contact details

Leiden University Medical Center (LUMC)
Department of Gastroenterology and Hepatology C-04-P
Room 192
P.O. Box 9600
Leiden
Netherlands
2300 RC
+31 (0)71 5261104
J.J.L.Haans@lumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

P05.170

Study information

Scientific Title

Acronym

BIG study

Study objectives

Several open-label pilot studies have shown a promising effect of intrapyloric botulinum toxin injection on symptoms in severe gastroparesis. However, data from randomized, double-blind, placebo-controlled studies are not yet available. We intend to evaluate the clinical efficacy of a single intrapyloric injection of botulinum toxin type A in patients with idiopathic gastroparesis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

A randomized, double-blind, placebo-controlled, multicenter trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Idiopathic gastroparesis

Interventions

Intrapyloric injection of botulinum toxin type A 200 IU single injection or placebo single injection. Scintigraphy for solid/liquid gastric emptying (before and after treatment).

Gastroparesis cardinal symptom index questionnaire
Quality of life (QOL) questionnaires
Psychometric assessment and patient perception questionnaires

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Botulinum toxin

Primary outcome measure

Gastric emptying for solids.

1. Half-emptying time at visit 4 (follow-up: week 6) compared to visit 1b (eligibility: week 1)
2. Emptying rate per hour at visit 4 (follow-up: week 6) compared to visit 1b (eligibility: week 1)
3. One, two and four hour meal retention at visit 4 (follow-up: week 6) compared to visit 1b (eligibility week 1).

Gastroparesis cardinal symptom index (GCSI) outcome

4. Total GCSI score at visit 3, 4, 5 and 6 (follow-up: week 3, 6, 9 and 12) compared to visit 2 (randomization: week 0)
5. Mean GCSI score during follow-up (week 0-12) compared to mean GCSI score during eligibility and randomization (week 10)

Secondary outcome measures

1. Gastric emptying for liquids; retention of liquid phase at 15, 30, 45, 60, 75, 90, 105 and 120 min
2. Quality of life as measured with the patient assessment of upper gastrointestinal disorders - quality of life (PAGI-QoL), the RAND-36 and EQ-5D questionnaires
3. Psychometric assessment and patient perception of gastrointestinal endoscopy

Overall study start date

01/06/2006

Completion date

01/06/2007

Eligibility

Key inclusion criteria

Patients are eligible to participate in this study if all of the following criteria are met:

1. Presence of clinical symptoms associated with idiopathic gastroparesis: nausea, vomiting, early satiety, postprandial fullness and a Gastroparesis Cardinal Symptom Index (GCSI) score ≥ 1 at visit 1b (eligibility; week 1)
2. Delayed gastric emptying for solids at visit 1b (eligibility; week 1) as measured with scintigraphy:
 - a. 2h retention $\geq 60\%$; and/or
 - b. 4h retention $\geq 10\%$
3. Absence of an obstructing structural lesion in the stomach or small intestine at prior diagnostic gastrointestinal endoscopy (performed within the previous 5 years) or judged absent

by the responsible physician

4. Patients, both male and female, must use adequate means of birth control during the study

5. Patients must provide written informed consent prior to any study procedures being performed

6. Patients aged between 18 and 70 years inclusive

7. Patients, in the opinion of the investigator, must be able to understand the study and comply with the study requirements

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

48

Key exclusion criteria

Patients are excluded from the study if any of the following criteria are met:

1. Patients with predominant abdominal pain/discomfort in the opinion of the investigator

2. Presence of an obstructing structural lesion in the stomach or small intestine if observed during treatment gastrointestinal endoscopy (visit 2, randomization; week 0)

3. Patients taking drugs that interfere with the effect of botulinum toxin type A

4. Patients previously treated with intrapyloric injection of botulinum toxin type A;

5. Females who are pregnant or lactating

6. Patients with diabetes mellitus

7. Patients with delayed gastric emptying due to systemic disorders, e.g. systemic lupus erythematosus (SLE), sclerodermia, hypothyroidism

8. Patients with disorders of neuromuscular transmission, e.g. myasthenia gravis and Eaton-Lambert syndrome

9. Patients with abdominal surgery in their medical history, except (laparoscopic) appendectomy, (laparoscopic) cholecystectomy and/or hysterectomy

10. Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for entry into the study

Date of first enrolment

01/06/2006

Date of final enrolment

01/06/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

Leiden University Medical Center (LUMC)

Leiden

Netherlands

2300 RC

Sponsor information

Organisation

Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology (The Netherlands)

Sponsor details

P.O. Box 9600

Leiden

Netherlands

2300 RC

Sponsor type

University/education

ROR

<https://ror.org/05xvt9f17>

Funder(s)

Funder type

University/education

Funder Name

Leiden University Medical Center (LUMC) Department of Gastroenterology and Hepatology

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration